This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q77.5 (diastrophic dysplasia) | Special Copayment Reduction: V228 (rare disease) |
| B. Synonyms | Diastrophic dysplasia, diastrophic dwarfism, Diastrophic nanism |
| C. Adult onset | Likelihood of first onset in adulthood very low — diagnosed at birth or prenatally; complications (scoliosis, joint contractures) can continue to progress in adulthood. |
| 1. History | 1960 first described by Lamy and Maroteaux → 1994 Hästbacka identified the SLC26A2 gene → mechanism of defective sulfate transport elucidated. |
| 2. Causes | SLC26A2 (DTDST) gene variants. Autosomal recessive. Defective sulfate transport → impaired sulfation of cartilage proteoglycans → abnormal cartilage matrix. |
| 3. Genetics | SLC26A2: 5q32-q33.1, autosomal recessive. Finnish founder mutation (IVS1+2T>C). Same-gene spectrum: DTD, SEMD, ACG-1B, AO-2. |
| 4. General epidemiology | 1–2 per 100,000 births. High frequency in Finland (founder effect). Extremely rare in Korea. Estimated several thousand worldwide. |
| 5. Pathophysiology | Loss of SLC26A2 (sulfate/chloride exchanger) function → intracellular sulfate deficiency → reduced production of sulfated cartilage GAGs (CS, HS) → weakened growth plate and articular cartilage matrix. |
| 6. Symptoms | Short-limbed dwarfism, hitchhiker thumb, cauliflower ear (ear cysts in infancy → deformity), clubfoot (equinovarus), scoliosis/kyphosis, cervical spine instability. |
| 7. Signs | Joint contractures (multiple), lateral deviation at the proximal interphalangeal joints of the fingers, cleft palate (about 50%), rigid scoliosis (progressive Cobb angle), cervical kyphosis/instability. MRI findings. |
| 8. Screening | Prenatal ultrasound (short limbs, clubfoot, thumb abnormalities). High-risk families: molecular genetic prenatal diagnosis of SLC26A2. |
| 9. Diagnosis | Clinical and radiographic findings + molecular genetic confirmation of SLC26A2. Sulfate transport assay in skin fibroblasts (research). Differential: achondroplasia, rhizomelic dwarfism. |
| 10. Treatment | No curative treatment. Clubfoot surgery (soft tissue release, osteotomy), scoliosis surgery (posterior spinal fusion), fixation of cervical instability, cleft palate surgery, physical therapy. |
| 11. Prognosis | Nonlethal; life expectancy nearly normal. Main complications: progressive scoliosis, cervical instability (rarely spinal cord injury). Ambulation possible, but joint pain and limitation persist. |
| 12. Prevention | Genetic counseling, preimplantation genetic testing (PGT), prenatal SLC26A2 analysis. Regular spinal, cervical, and joint assessment to prevent complications. |
| 13. References | Hästbacka J et al. Nat Genet 1994; Superti-Furga A et al. Nat Genet 1996; Rossi A et al. Am J Hum Genet 1998 … and 7 others |
Diastrophic dysplasia (DTD) was first described as a distinct disease in 1960 by the renowned French skeletal dysplasia researchers Maurice Lamy and Pierre Maroteaux. Noting the characteristic limb flexion deformities and complex joint abnormalities of the disease, they gave it the name 'diastrophic', derived from a Greek word meaning 'to distort'. It had previously been classified as a variant of achondroplasia, but Lamy and Maroteaux argued that it was a distinct disease on the basis of its unique clinical signs (hitchhiker thumb, ear cysts, cleft palate, etc.).
Over the following decades, its clinical and radiographic features were described in detail, and in the 1980s the fact that the disease occurs markedly more frequently in Finland than in other regions drew attention. The high frequency in Finland was explained as part of the 'Finnish disease heritage' phenomenon, in which founder variants derived from a small founder population are maintained at high frequency within the population.
The molecular pathogenesis was elucidated in 1994 when Johanna Hästbacka et al. of the University of Helsinki, Finland, narrowed the location of the DTD causative gene on chromosome 5, identified the SLC26A2 (DTDST, Diastrophic Dysplasia Sulfate Transporter) gene, and confirmed the Finnish founder mutation (IVS1+2T>C, a splicing variant). In 1996, Andrea Superti-Furga et al. showed that this gene encodes a sulfate transporter and that its loss of function impairs the production of sulfated proteoglycans in the cartilage matrix, clarifying the pathogenic mechanism. Subsequent studies established that, depending on the severity of variants in the same SLC26A2 gene, there is a spectrum ranging from multiple epiphyseal dysplasia (SEMD, Multiple epiphyseal dysplasia), milder than diastrophic dysplasia, to the lethal achondrogenesis type IB (ACG-1B) and atelosteogenesis type II (AO-2).
To date, no curative treatment for diastrophic dysplasia has been developed, and treatment focuses on symptom management and prevention of complications. Research targeting the sulfate transport pathway and cell therapy research for reconstruction of the cartilage matrix are under way, but further research is needed before clinical application.
Diastrophic dysplasia is an autosomal recessive genetic disease caused by biallelic pathogenic variants in the SLC26A2 (Solute Carrier Family 26, Member 2) gene located on chromosome 5 (5q32-q33.1). SLC26A2 was previously called DTDST (Diastrophic Dysplasia Sulfate Transporter) and encodes an anion transporter that carries sulfate and chloride ions across the cell membrane.
The SLC26A2 protein actively imports sulfate into the cell at the cell membrane. In chondrocytes, this transport function supplies the sulfate essential for synthesis of sulfated proteoglycans — chondroitin sulfate (CS), heparan sulfate (HS), and keratan sulfate (KS) — the key components of the cartilage matrix. When SLC26A2 function is impaired, intracellular sulfate concentration falls, production of sulfated proteoglycans decreases markedly, and the structural integrity of the cartilage matrix is compromised.
Various variants have been reported in the SLC26A2 gene. The Finnish founder mutation IVS1+2T>C (a splicing variant) accounts for most Finnish DTD patients and is also the most common variant worldwide. Many other variants have been reported, including R279W, A386V, C653S, and exon 6 deletion. Compound heterozygosity, with two different pathogenic variants transmitted from the father and mother respectively, is common. Clinical severity is determined by the type of variant and the residual sulfate transport activity.
Across the variant spectrum of the same SLC26A2 gene, the clinical phenotype varies in proportion to the amount of residual protein function. The greater the loss of function, the more lethal the phenotype (ACG-1B > AO-2 > DTD > SEMD), and relatively milder DTD or SEMD phenotypes occur with variants that retain some residual sulfate transport activity. This continuous spectrum allows SLC26A2-related skeletal dysplasias to be understood as a single disease continuum.
The SLC26A2 gene is located on the long arm of chromosome 5 (5q32-q33.1), is about 57 kb in size, and consists of 3 exons (the main coding sequence is in exons 2 and 3). The encoded protein is an anion exchange transporter of 739 amino acids with 12 transmembrane domains that exchanges extracellular sulfate (SO4²⁻) for intracellular chloride (Cl⁻) or other anions. SLC26A2 belongs to the SLC26 anion transporter multiprotein family and structurally has a STAS (Sulfate Transporter and Anti-Sigma factor antagonist) domain at its C-terminus.
The mode of inheritance is autosomal recessive. When both parents are carriers (heterozygous, asymptomatic), 25% of children have homozygous or compound heterozygous variants and develop the disease. Most patients are compound heterozygotes, inheriting a different variant from each parent.
In order of clinical severity, the SLC26A2-related disease spectrum consists of ① achondrogenesis type IB (ACG-1B, lethal, perinatal death), ② atelosteogenesis type II (AO-2, lethal or survivable), ③ diastrophic dysplasia (DTD, nonlethal), and ④ multiple epiphyseal dysplasia (SEMD, mildest). Even among DTD patients, there is a range of severity from mild to severe DTD depending on the variant. Therefore, molecular genetic confirmation and identification of the variant type are important for prognostic prediction and genetic counseling.
In Finland, the carrier frequency of the founder mutation IVS1+2T>C is high at about 1/70, so the incidence of DTD in this population is 1/33,000, markedly higher than in other regions (1/100,000–1/500,000). In non-Finnish European populations, R279W (c.835C>T) is the second most common variant. The variant spectrum in East Asian populations, including Korea, may differ from that in Europe, and whole-gene NGS panel analysis is an appropriate diagnostic approach.
The worldwide incidence of diastrophic dysplasia is estimated at about 1–2 per 100,000 births. However, regional differences are large; in Finland in particular, the founder mutation effect results in a high incidence of about 1/33,000. In non-Finnish regions, it is much rarer, at about 1 per 100,000–500,000 births. There is no difference in incidence between males and females.
The number of patients worldwide is difficult to count precisely, but is estimated at several thousand to fewer than 10,000. Relatively systematic patient registries and cohort studies exist in Europe and North America, and in Finland, long-term follow-up cohort studies have accumulated data on the natural history, occurrence of complications, and quality of life. Systematically compiled data on patient numbers and epidemiology in East Asia, including Korea, are limited, and in Korea it is an extremely rare disease.
Because of autosomal recessive inheritance, the disease manifests in a child only when both parents are carriers. Incidence may increase in populations with a high frequency of consanguineous marriage or with a high carrier frequency for specific variants due to a founder effect. With advances in prenatal ultrasound and molecular genetic technology, the prenatal diagnosis rate is rising, which allows a multidisciplinary management plan to be prepared for birth. When characteristic findings (short limbs, clubfoot, hitchhiker thumb) are observed on fetal ultrasound, it is recommended to suspect DTD and perform molecular genetic testing.
The core pathogenesis of diastrophic dysplasia is deficiency of sulfated proteoglycans in the cartilage matrix due to defective sulfate transport. Normal chondrocytes take up extracellular sulfate through the SLC26A2 transporter and use it as the substrate for the reaction in the Golgi apparatus in which sulfotransferases transfer sulfate groups to glycosaminoglycan (GAG) chains — mainly chondroitin sulfate and heparan sulfate. Sulfated GAGs are covalently attached to proteoglycan core proteins such as aggrecan and perlecan and determine the water retention, compressive resistance, and growth factor-binding capacity of the cartilage matrix.
When SLC26A2 function is lost, intracellular inorganic sulfate concentration falls markedly. As a result, the degree of sulfation of the proteoglycans secreted by chondrocytes decreases, and an undersulfated cartilage matrix is formed. This undersulfated matrix has lower water retention and mechanical strength than normal cartilage, and the normal proliferation, differentiation, and hypertrophy of chondrocytes within the growth plate are disturbed. As a result, longitudinal growth of the long bones is impaired, and the structural integrity of the articular cartilage is compromised, so joint contractures and deformities appear from birth.
Hitchhiker thumb is a characteristic finding in which the thumb is extremely abducted and flexed due to abnormal joint development between the proximal phalanx of the thumb and the metacarpal. Auricular cysts are a phenomenon in infancy in which cystic structures form within the cartilage of the auricle, which becomes swollen and hard; the ear cartilage later calcifies and deforms into a 'cauliflower ear'. These ear cysts are an almost pathognomonic finding of GTD and are related to a local inflammatory response due to impaired sulfation of the cartilage matrix. Cleft palate is explained as arising when cartilage matrix abnormalities interfere with palatal fusion during fetal palatal development.
Scoliosis results from cartilage matrix abnormalities of the vertebral bodies and intervertebral discs and often progresses from birth. Cervical abnormalities (C-shaped cervical kyphosis or cervical instability) result from abnormal development of the atlantoaxial joint and odontoid process, and in severe cases there is a risk of spinal cord compression. Clubfoot (talipes equinovarus) results from a combination of abnormal cartilage formation in the heel and ankle joints and contracture of the surrounding soft tissues.
The clinical symptoms of diastrophic dysplasia are evident from birth and are characterized by widespread skeletal abnormalities. Severity varies between affected individuals, but the core phenotype appears consistently.
Dwarfism: Short-limbed dwarfism, with marked limb shortening, though less severe than in achondroplasia. Final adult height is mostly in the range of 110–130 cm. Limb shortening shows a rhizomelic pattern, with the proximal segments (upper arm, thigh) relatively more affected than the distal segments (forearm, lower leg), but this is less pronounced than in achondroplasia.
Hitchhiker thumb: The most characteristic finding of diastrophic dysplasia. The thumb is extremely abducted and flexed, giving the appearance of a 'hitchhiking' posture. The proximal phalanx of the thumb is short and triangular, and the first metacarpophalangeal joint is abnormally developed. This finding is almost specific to diastrophic dysplasia and provides an important diagnostic clue.
Ear abnormalities: In infancy (a few weeks to a few months after birth), cystic swelling of the auricle (auricular cyst) develops; it resolves spontaneously after an inflammatory reaction, but the ear cartilage then calcifies, hardens, and deforms into a 'cauliflower ear'. This change is a pathologically highly specific finding of diastrophic dysplasia. Ear malformations can cause otitis media and hearing problems.
Clubfoot (talipes equinovarus): Bilateral clubfoot is present from birth in most patients, and because soft tissue and bone abnormalities are combined, it is difficult to correct. Casting, resection, and surgical correction are often repeated.
Spinal abnormalities: Scoliosis progresses from childhood and may continue to worsen in adulthood. In some, it progresses rapidly, causing restricted pulmonary function and cardiopulmonary complications. Cervical kyphosis or cervical instability is present, with a risk of spinal cord compression. Thoracolumbar kyphosis may also occur.
Joint contractures: Multiple joint contractures appear in the shoulders, elbows, hips, and knees, limiting range of motion. This results from a combination of impaired joint development due to cartilage matrix abnormalities and shortening of the surrounding soft tissues.
Cleft palate: Cleft palate occurs in about 50% of all patients and causes feeding difficulties, delayed speech development, and recurrent otitis media. Cleft lip is rare.
The physical and radiographic signs of diastrophic dysplasia appear widely throughout the skeletal system, and some signs change with age.
Musculoskeletal physical signs: The dysmorphic hitchhiker thumb is clearly visible on inspection. Lateral deviation at the proximal interphalangeal joints of the fingers, multiple joint contractures, knee flexion contractures, hip flexion-abduction contractures, and limited elbow extension are observed. Rigid clubfoot (rigid equinovarus) is difficult to correct manually. Abnormal curvature throughout the spine is identified by inspection and palpation, and the degree of scoliosis is quantified by the Cobb angle.
Ear signs: Auricular cysts in infancy appear as soft, fluctuant cystic swellings, characteristically occurring without signs of infection such as fever. Later, the calcified, hardened ear cartilage feels hard on palpation, and ear deformity is clearly visible.
Radiographic signs: A skeletal survey shows short, broad long bones, a triangular proximal phalanx (hitchhiker thumb), epiphyseal irregularity, abnormal vertebral development (abnormal shape, narrowed pedicles), platyspondyly, and abnormal shape of the iliac wings. Cervical radiographs and MRI assess atlantoaxial instability, odontoid dysplasia, and findings of spinal cord compression.
Cleft palate and oral findings: Oral examination identifies a soft or hard palate cleft, and soft palate dysfunction is assessed by nasopharyngoscopy. When cleft palate is present, feeding difficulties, hypernasal speech, and recurrent otitis media occur.
Pulmonary function: When severe scoliosis and chest wall deformity are present, pulmonary function testing (spirometry) may show a restrictive pattern. Regular pulmonary function assessment from childhood is recommended.
Neurologic signs: When there is spinal cord compression due to severe cervical instability or kyphosis, limb weakness, hyperreflexia, sensory abnormalities, and bladder and bowel dysfunction may appear. This requires immediate imaging assessment and neurosurgical intervention.
Diastrophic dysplasia is not a target of population-wide screening; systematic screening is performed in high-risk groups (family history, abnormal prenatal ultrasound findings).
Prenatal ultrasound: Diastrophic dysplasia is suspected when findings such as limb shortening, bilateral clubfoot, hitchhiker thumb (excessive abduction of the thumb on fetal hand ultrasound), and a narrow chest are observed on standard prenatal ultrasound. Ear cysts appear after birth and therefore cannot be seen on prenatal ultrasound. Fetal ultrasound findings alone may not distinguish lethal skeletal dysplasias (ACG-1B, AO-2) from nonlethal DTD, so molecular genetic testing is needed.
Molecular genetic prenatal diagnosis: When both parents are confirmed carriers of SLC26A2 variants, fetal DNA is obtained by chorionic villus sampling at 11–14 weeks of gestation or amniocentesis at 15–20 weeks and analyzed for SLC26A2 variants. Active prenatal diagnosis is recommended for carrier parents, which can confirm whether the fetus is affected and its severity (whether it is a homozygous lethal form).
Preimplantation genetic testing (PGT): In carrier couples, it can be performed together with in vitro fertilization to screen out embryos affected by SLC26A2 variants.
Postnatal clinical screening: Because de novo variants are rare and most patients are born to carrier parents, clinical assessment and molecular genetic confirmation should be performed right after birth when there is a family history. Even when born without ultrasound abnormalities, if there is a combination of hitchhiker thumb, ear cysts, and clubfoot, DTD is suspected immediately and confirmatory testing is performed.
Diagnosis of diastrophic dysplasia proceeds in steps: identification of characteristic clinical and radiographic findings, followed by confirmation with SLC26A2 molecular genetic analysis.
Clinical diagnostic criteria: ① short-limbed dwarfism, ② hitchhiker thumb, ③ ear cysts or cauliflower ear, ④ bilateral clubfoot, ⑤ scoliosis/cervical abnormalities, ⑥ multiple joint contractures, ⑦ cleft palate. Of these, the combination of hitchhiker thumb and ear cysts (cauliflower ear) is highly specific for diastrophic dysplasia.
Radiographic diagnosis: A skeletal survey identifies short long bones, triangular deformity of the proximal phalanx, spinal abnormalities, and abnormal pelvic shape. Assessment of the atlantoaxial joint and spinal cord by cervical radiography and MRI is essential at an early stage.
Molecular genetic confirmation: Biallelic variants are identified using an NGS-based skeletal dysplasia panel or SLC26A2 single-gene analysis. In Finnish or European patients, common variants such as the Finnish founder variant (IVS1+2T>C) and R279W are analyzed first. In Korean patients, whole-gene NGS analysis is recommended. The diagnosis is confirmed when pathogenic variants are identified on both alleles.
Research testing: Measurement of sulfate transport activity after culture of skin fibroblasts may be performed for research purposes but is not used routinely in clinical practice.
Differential diagnosis: Differentiate from achondroplasia (FGFR3, no hitchhiker thumb), rhizomelic dwarfism (different mechanism), other SLC26A2-related disorders (ACG-1B, AO-2 — more severe phenotype, lethal), and other skeletal dysplasias with multiple joint contractures.
There is currently no curative treatment for diastrophic dysplasia, and treatment focuses on a multidisciplinary approach aimed at managing complications and improving function.
Treatment of clubfoot: The Ponseti method may be effective in mild to moderate cases, but because clubfoot in DTD is very rigid, surgical treatment is mostly required. Soft tissue release, posteromedial release, Achilles tendon lengthening, and the like are performed in stages. Osteotomy is needed for recurrence in adults. Maintaining the ability to walk is the treatment goal.
Treatment of scoliosis and the cervical spine: Bracing can slow progression of mild scoliosis, but its fundamental preventive effect is limited. Posterior spinal fusion is performed for curves with a Cobb angle of 40–50 degrees or more or rapidly progressing curves. When cervical kyphosis or atlantoaxial instability is present, cervical fusion is needed, and emergency surgery is required with signs of spinal cord compression. Because intraoperative airway management is particularly difficult, an experienced anesthesia team is needed.
Cleft palate surgery: Following general cleft palate surgery principles, palatoplasty is performed between 9 and 18 months of age. Speech therapy, hearing management, and tympanostomy tube insertion are provided concurrently.
Management of joint contractures: Range of motion is maintained through physical and occupational therapy, night splints, and orthoses. Soft tissue release is considered for severe hip flexion contractures.
Pain management: Acetaminophen, COX-2 inhibitors, physical therapy, and aquatic exercise are used for chronic joint pain in adulthood. Opioids are used cautiously for chronic pain.
Assistive technology and mobility aids: Daily function and independence are maximized through assistive technology such as walking aids, custom footwear, and modified handles.
Diastrophic dysplasia is a nonlethal skeletal dysplasia, and apart from respiratory failure in infancy or acute spinal cord injury due to cervical instability, life expectancy is nearly the same as in the general population. Intellectual ability is normal, and education, employment, and social participation are possible. However, various musculoskeletal complications and chronic pain greatly affect quality of life.
Ambulation and mobility: According to long-term Finnish cohort studies, about 50–70% of adult DTD patients can walk independently, and the rest use orthoses or wheelchairs. The success of clubfoot correction, the degree of scoliosis progression, and the severity of joint contractures are the main factors determining ambulation.
Spinal complications: Progressive scoliosis is the most important long-term complication. Without surgical correction, restricted pulmonary function, chronic pain, and cardiopulmonary complications may develop. Cervical instability is rare but carries a risk of serious spinal cord injury, so regular assessment and prophylactic fixation are important.
Chronic pain and quality of life: In adulthood, multiple joint pain, low back pain, and radiating leg pain are common and are major factors reducing quality of life. Ongoing pain management and rehabilitation are needed. Psychological adjustment, social support, and participation in patient organizations help maintain a positive quality of life.
Respiratory: Respiratory failure due to a narrow chest in infancy can rarely be fatal, and in adults severe scoliosis can cause restrictive lung disease. Regular pulmonary function testing and, when needed, noninvasive positive pressure ventilation (NIV) are recommended.
Primary prevention of diastrophic dysplasia is possible only through genetic intervention, and most prevention strategies focus on early detection and treatment of complications.
Primary prevention — genetic counseling and genetic testing: Siblings and parents of affected patients, or carrier couples planning children, discuss the recurrence risk (25% of children for carrier couples) and the options of prenatal diagnosis and preimplantation genetic testing (PGT) through genetic counseling. When an SLC26A2 variant has been identified in the family, carrier status is determined by molecular genetic testing and reflected in future pregnancy plans.
Early prenatal diagnosis: In pregnancies of carrier couples, SLC26A2 variants are identified by chorionic villus sampling or amniocentesis to recognize an affected fetus early, so that a multidisciplinary management team (pediatric orthopedics, pediatrics, genetic counselor, pulmonology) can prepare for the birth before delivery.
Secondary prevention — early detection of complications: Right after birth, cervical instability is assessed with cervical radiographs and MRI, and progression of scoliosis is followed with periodic spinal radiographs. Polysomnography checks for sleep apnea, and hearing tests detect conductive hearing loss early. Correction of clubfoot begins in the neonatal period.
Tertiary prevention — maintaining function: Maintain range of motion through physical and occupational therapy; minimize joint loading through weight management; maintain walking function with custom orthoses and footwear; detect and treat worsening complications early through regular multidisciplinary follow-up.
Hästbacka J, de la Chapelle A, Mahtani MM, et al. The diastrophic dysplasia gene encodes a novel sulfate transporter: positional cloning by fine-structure linkage disequilibrium mapping. Cell. 1994;78(6):1073-1087. DOI: 10.1016/0092-8674(94)90281-x. PMID: 7923362.
Superti-Furga A, Hastbacka J, Wilcox WR, et al. Achondrogenesis type IB is caused by mutations in the diastrophic dysplasia sulphate transporter gene. Nat Genet. 1996;12(1):100-102. DOI: 10.1038/ng0196-100. PMID: 8528239.
Rossi A, Superti-Furga A. Mutations in the diastrophic dysplasia sulfate transporter (DTDST) gene (SLC26A2): 22 novel mutations, mutation review, associated skeletal phenotypes, and diagnostic relevance. Hum Mutat. 2001;17(3):159-171. DOI: 10.1002/humu.5. PMID: 11241838.
Makitie O, Kaitila I. Growth in diastrophic dysplasia. J Pediatr. 1997;130(4):641-646. DOI: 10.1016/s0022-3476(97)70249-9. PMID: 9108868.
Poussa M, Merikanto J, Ryoppy S, et al. The spine in diastrophic dysplasia. Spine (Phila Pa 1976). 1991;16(8):881-887. PMID: 1948385.
Ryoppy S, Poussa M, Merikanto J, et al. Foot deformities in diastrophic dysplasia. An analysis of 102 patients. J Bone Joint Surg Br. 1992;74(3):441-444. DOI: 10.1302/0301-620X.74B3.1587895. PMID: 1587895.
Lamy M, Maroteaux P. Le nanisme diastrophique. Presse Med. 1960;68:1977-1980. [French original description]
Bonafe L, Cormier-Daire V, Hall C, et al. Nosology and classification of genetic skeletal disorders: 2015 revision. Am J Med Genet A. 2015;167A(12):2869-2892. DOI: 10.1002/ajmg.a.37365. PMID: 26394607.
Cormier-Daire V. Diastrophic dysplasia: clinical and molecular aspects. Orphanet J Rare Dis. 2008;(GeneReviews reference). PMID reference available via NCBI GeneReviews.
Superti-Furga A, Bonafe L, Rimoin DL. Molecular-pathogenetic classification of genetic disorders of the skeleton. Am J Med Genet. 2001;106(4):282-293. DOI: 10.1002/ajmg.10233. PMID: 11891680.